There have been many punishing pandemic chapters in 2020 — the beginning, the global spread, mass death in springtime and beyond, lockdowns and economies battered, reopenings and alarming resurgences. This week, the vaccine quantum leap has offered the promise of light at the end of a dark tunnel.
Pfizer’s COVID-19 vaccine, which was co-developed with Germany’s BioNTech, faces one final and critical hurdle before an expected decision to greenlight the shot for use in millions of Americans. Food and Drug Administration advisers meet today to scrutinize the company’s data for any red flags or oversights.
Safety will be the top priority for the panel of medical experts who will vote on whether to endorse the vaccine. They will also address unknowns about the vaccine’s effectiveness in certain groups. A final FDA decision and the first shots could follow within days, Lauran Neergaard and Matthew Perrone report.
U.S. Vaccine Poll: A new survey from The AP-NORC Center for Public Affairs Research has found only about half of Americans are ready to roll up their sleeves for COVID-19 vaccines even as states frantically prepare to begin months of vaccinations that could end the pandemic. The poll shows about a quarter of U.S. adults aren’t sure if they want to get vaccinated when their turn comes. Roughly another quarter say they won’t, Lauran Neergaard and Hannah Fingerhut report.